Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
BioNTech SE (STU:22UA) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
BioNTech SE Capex-to-Operating-Cash-Flow Related Terms
BioNTech SE Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:22UA vs RPRX, INSM, ROIV: Capex-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, BioNTech SE's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Capex-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.00 mean?
BioNTech SE (STU:22UA) has a Capex-to-Operating-Cash-Flow of 0.00 as of Mar. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on BioNTech SE and its competitors. Over the past decade, BioNTech SE's Capex-to-Operating-Cash-Flow has ranged from 0.03 to 2.18. According to the industry distribution chart, BioNTech SE ranks #98 out of 245 companies in the Biotechnology industry, placing it in the top 40%.
Is BioNTech SE's Capex-to-Operating-Cash-Flow too high?
BioNTech SE's current Capex-to-Operating-Cash-Flow is 0.00. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 2.18. Based on the distribution chart, BioNTech SE ranks #98 out of 245 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Capex-to-Operating-Cash-Flow compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #98 out of 245 companies for Capex-to-Operating-Cash-Flow. This puts BioNTech SE in the upper half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.35. Historically, BioNTech SE's own Capex-to-Operating-Cash-Flow has ranged from 0.03 to 2.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Biotechnology company?
The median Capex-to-Operating-Cash-Flow among Biotechnology companies is 0.35, based on 245 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Cash-Flow is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Capex-to-Operating-Cash-Flow is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (STU:22UA) is currently considered Fairly Valued. The stock's GF Value™ is €78.33, compared to a current price of €79.50 — trading 1.5% above its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.00. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For BioNTech SE (STU:22UA), the current Capex-to-Operating-Cash-Flow is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (STU:22UA) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of €79.50 is trading 1.5% above its estimated GF Value™ of €78.33.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for STU:22UA:
Capex-to-Operating-Cash-Flow: 0.00
GF Value™: €78.33 vs. price of €79.50 (1.5% above fair value)
No single metric tells the full story. See the STU:22UA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for STU:22UA
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:22UA has been successfully added to your 
